Evolus CFO Sandra Beaver resigns for new role

Evolus (EOLS) announced CFO Sandra Beaver's resignation, effective June 13, 2025, as she departs to join a private mental health technology firm; the exit is not due to disagreements with Evolus. Despite a recent Q1 2025 EPS miss of -$0.30 versus a -$0.09 forecast, revenue grew 15.5% year-over-year to $68.5 million, and the company reaffirmed its full-year revenue guidance of $345-$355 million, targeting $700 million by 2028. Evolus is actively searching for Beaver's successor and highlighted the successful launch of Evolisse and EU MDR approval for Estyme®.

Analysis

Evolus, Inc. (NASDAQ: EOLS) announced the planned departure of its CFO, Sandra Beaver, effective June 13, 2025, to join a private entity; importantly, this resignation is not linked to any operational or financial disagreements within Evolus. The company exhibits robust financial stability, evidenced by a current ratio of 2.34, and has demonstrated significant growth with a 25.38% increase in revenue over the last twelve months, reaching $275.46 million. Despite this strong revenue trajectory and the successful launch of its second product line, Evolisse, recent Q1 2025 results revealed a larger-than-anticipated loss with an EPS of -$0.30, missing the -$0.09 forecast, and revenue of $68.5 million, which, while up 15.5% year-over-year, fell short of the $72.51 million consensus. Evolus has reaffirmed its full-year 2025 revenue guidance of $345-$355 million and maintains a long-term target of $700 million in net revenue by 2028, supported by the Evolisse launch (projected 8-10% of 2025 revenue) and upcoming European expansion with Estyme® HA gels following EU MDR approval. While analyst price targets suggest potential upside ($20-$27 per share), the stock is currently trading near its InvestingPro Fair Value, indicating a mixed near-term outlook amidst management transition and recent earnings performance.

Key Decisions for Investors

• Investors should monitor the progress of the CFO search and the subsequent integration of new financial leadership, as stability in this key role is crucial during a growth phase.
• Closely track the revenue contribution and market adoption of new products, Evolisse and Estyme®, particularly in light of the company's reaffirmed guidance and long-term revenue targets.
• Evaluate the company's ability to achieve profitability and manage market softness, weighing the recent EPS miss against the strong underlying revenue growth and positive product pipeline developments.